

GLAXOSMITHKLINE PLC
Form 6-K
November 27, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 27 November 2018

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No ☒

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 27 November 2018

Name of applicant: GlaxoSmithKline plc

Name of scheme: GlaxoSmithKline plc 2009 Deferred
Annual Bonus Plan

Period of return: From: 1 May 2018 To: 31 October 2018

Balance of unallotted
securities under Previous balance: 33,863*
scheme(s) from previous Restated balance: -27,669
return:

Plus: The amount by
which the block
scheme(s) has been
increased since the date of 575,000
the last return (if any
increase has been applied
for):

Less: Number
of securities issued/allotted
under scheme(s) during 0
period (see LR3.5.7G):

Equals: Balance under
scheme(s) not yet 547,331
issued/allotted at end of
period:

Name of contact: Victoria
Whyte

Telephone number of contact: 020 8047
5000

*Due to clerical error the opening balance has been restated.

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 27 November 2018

Name of applicant: GlaxoSmithKline plc

Name of scheme: GlaxoSmithKline Share Option Plan -
Ordinary Shares

Period of return: From: 1 May 2018 To: 31 October 2018

Balance of unallotted
securities under Previous balance: 2,693,951*
scheme(s) from previous Restated balance: 2,755,483
return:

Plus: The amount by
which the block
scheme(s) has been
increased since the date of
the last return (if any
increase has been applied
for):

Less: Number
of securities issued/allotted
under scheme(s) during 532,131
period (see LR3.5.7G):

Equals: Balance under
scheme(s) not yet 2,223,352
issued/allotted at end of
period:

Name of contact: Victoria
Whyte

Telephone number of contact: 020 8047
5000

*Due to clerical error the opening balance has been restated.

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 27 November 2018

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Name of applicant: GlaxoSmithKline plc

Name of scheme: GlaxoSmithKline Share Option Plan -
ADS

Period of return: From: 1 May 2018 To: 31 October 2018

Balance of unallotted
securities under
scheme(s) from previous
return: 7,909,994

Plus: The amount by
which the block
scheme(s) has been
increased since the date of
the last return (if any
increase has been applied
for):

Less: Number
of securities issued/allotted
under scheme(s) during
period (see LR3.5.7G): 573,898

Equals: Balance under
scheme(s) not yet
issued/allotted at end of
period: 7,336,096

Name of contact: Victoria
Whyte

Telephone number of contact: 020 8047
5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 27 November 2018

Name of applicant: GlaxoSmithKline plc

Name of scheme: GlaxoSmithKline plc Share Save Plan
2012

Period of return: From: 1 May 2018 To: 31 October 2018

Balance of unallotted
securities under
scheme(s) from previous
return: 827,306

Plus: The amount by
which the block
scheme(s) has been
increased since the date of 5,000,000
the last return (if any
increase has been applied
for):

Less: Number
of securities issued/allotted
under scheme(s) during
period (see LR3.5.7G): 154,683

Equals: Balance under
scheme(s) not yet
issued/allotted at end of
period: 5,672,623

Name of contact: Victoria
Whyte

Telephone number of contact: 020 8047
5000

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: November 27, 2018

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

behalf of GlaxoSmithKline plc